TriangleWU-CART-007 (NCT06514794)
WU-CART-007 trial for T-cell Acute Lymphoblastic Leukemia (NCT06514794). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged six months or older with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Disease must be relapsed or refractory, or in remission with detectable residual disease. Prior CD7-directed treatment is excluded.
The idea: give one WU-CART-007 infusion after lymphodepletion, which reduces immune cells. These donor-derived T cells are engineered to recognize CD7 on tumor cells and attack them. Researchers assess complete remission or clearance of residual disease, depending on the starting group.
This phase 2 study plans 125 patients. Allotera Therapeutics sponsors sixteen recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.